Atrial Fibrillation – New Frontiers in Anticoagulation

Title:Atrial Fibrillation – New Frontiers in Anticoagulation

Volume: 14 Issue: 1

Author(s): Ranji Thomas, Pierre Le Page and Andrew R.J. Mitchell

Affiliation:

Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.

Abstract: Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.

Cite this article as:

Thomas Ranji, Page Le Pierre and Mitchell R.J. Andrew, Atrial Fibrillation – New Frontiers in Anticoagulation, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/1871529X1401140724094846